News & Updates

Show Multimedia Only

$Vedolizumab–tofacitinib combo induces response in refractory UC$

Vedolizumab–tofacitinib combo induces response in refractory UC

22 Aug 2025

Patients with ulcerative colitis (UC) refractory to anti-TNF and second-line therapies appear to benefit from combination therapy with vedolizumab plus tofacitinib, with many of them achieving clinical remission, as shown in a study.

Vedolizumab–tofacitinib combo induces response in refractory UC

22 Aug 2025

Inflammatory diet ups risk of constipation

21 Aug 2025 by

Individuals with a high inflammatory diet are at increased risk of constipation, suggests a study. Moreover, gender and physical activity may influence such relationship.

Inflammatory diet ups risk of constipation

21 Aug 2025

Original New Drug Application Approvals by US FDA (16-31 July 2025)

19 Aug 2025

New drug applications approved by US FDA as of 16-31 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2025)

19 Aug 2025

No mortality benefit with longer antibiotic prophylaxis durations in cirrhosis, upper GI bleeds

15 Aug 2025

In patients with cirrhosis and upper gastrointestinal (GI) bleeds, mortality outcome does not differ between shorter and longer antibiotic prophylaxis durations, according to a systematic review and Bayesian meta-analysis.

No mortality benefit with longer antibiotic prophylaxis durations in cirrhosis, upper GI bleeds

15 Aug 2025

Anxiety, adaptive behaviours modify link between dysphagia, HDA in EoE

12 Aug 2025

Higher esophageal anxiety, use of adaptive behaviours, and hypervigilance are common among patients with active eosinophilic esophagitis (EoE), representing clinical markers of histological disease activity (HDA), a study has found.

Anxiety, adaptive behaviours modify link between dysphagia, HDA in EoE

12 Aug 2025

MASLD severity tied to poor cognitive function, HRQoL in patients with obesity

11 Aug 2025

Greater severity in metabolic dysfunction-associated steatotic liver disease (MASLD) may impair cognitive function and health-related quality of life (HRQoL) in patients with overweight or obesity, suggests a study.

MASLD severity tied to poor cognitive function, HRQoL in patients with obesity

11 Aug 2025

Adiposity levels may predict CRC risk

11 Aug 2025

High adiposity levels are associated with the risk of colorectal cancer (CRC), suggest the results of a systematic review. However, standardization is necessary to improve understanding of the link between CRC and adiposity to enable comparisons across papers.

Adiposity levels may predict CRC risk

11 Aug 2025

Outcomes after sleeve gastrectomy differ across race, ethnicities

09 Aug 2025

Glycaemic outcomes following sleeve gastrectomy (SG) vary by race and ethnicity, with non-Hispanic Black (NHB) participants showing less favourable outcomes, reports a study.

Outcomes after sleeve gastrectomy differ across race, ethnicities

09 Aug 2025

Vedolizumab vs adalimumab: Which works better for CD?

06 Aug 2025 by

Treatment with vedolizumab exhibits equivalent rates of response and mucosal healing but higher odds of drug persistence and achieving clinical remission compared with adalimumab in biologic-naïve patients with Crohn’s disease (CD), reports a study in a real-world setting.

Vedolizumab vs adalimumab: Which works better for CD?

06 Aug 2025

Healthy behaviours may prevent death in cirrhosis patients

05 Aug 2025

Keeping a healthy lifestyle such as having a balanced diet, regular exercise, and quality sleep may provide survival benefits to patients with cirrhosis, suggests a study.

Healthy behaviours may prevent death in cirrhosis patients

05 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

Vedolizumab–tofacitinib combo induces response in refractory UC

Vedolizumab–tofacitinib combo induces response in refractory UC

Inflammatory diet ups risk of constipation

Inflammatory diet ups risk of constipation

Original New Drug Application Approvals by US FDA (16-31 July 2025)

Original New Drug Application Approvals by US FDA (16-31 July 2025)

No mortality benefit with longer antibiotic prophylaxis durations in cirrhosis, upper GI bleeds

No mortality benefit with longer antibiotic prophylaxis durations in cirrhosis, upper GI bleeds

Anxiety, adaptive behaviours modify link between dysphagia, HDA in EoE

Anxiety, adaptive behaviours modify link between dysphagia, HDA in EoE

MASLD severity tied to poor cognitive function, HRQoL in patients with obesity

MASLD severity tied to poor cognitive function, HRQoL in patients with obesity

Adiposity levels may predict CRC risk

Adiposity levels may predict CRC risk

Outcomes after sleeve gastrectomy differ across race, ethnicities

Outcomes after sleeve gastrectomy differ across race, ethnicities

Vedolizumab vs adalimumab: Which works better for CD?

Vedolizumab vs adalimumab: Which works better for CD?

Healthy behaviours may prevent death in cirrhosis patients

Healthy behaviours may prevent death in cirrhosis patients